Table 3 When to use objective measurement in PD

From: Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease

1. Screening a (at risk) population to discover PD symptomatology that is poorly described or occult to the PwP and hence their clinician

If a PwP describes fluctuations that are not present with OM, this may indicate that they are predominantly non-motor fluctuations

PwP who have a higher risk of occult symptomatology include those who are:

at risk of dose-related (wearing-off) or unpredictable fluctuations, dyskinesia, or undertreated bradykinesia

unable to provide a clear history of symptoms

2. Objective assessment of the severity of symptomatology in PwP whose symptoms are known to be uncontrolled:

measuring the effect of a change in therapy to optimize their symptoms

assessing the severity and timing of reported symptomatology

identifying suitable candidates for advanced therapy (e.g., known fluctuations)

assessing symptomatology before or during the initiation of advanced therapy to improve titration to optimum dosages.

assessing the state of PwP who have high demands of health care resources

assessing PwP who are unable to communicate their symptom fluctuations, e.g., due to cognitive limitations

3. A means of communication. It will empower PwP by educating them about:

better recognition of their motor and non-motor symptoms

more effective interactions with their health care providers

Back to article page